ClariVest Asset Management LLC boosted its stake in shares of Halozyme Therapeutics Inc. (NASDAQ:HALO) by 15.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 91,204 shares of the biopharmaceutical company’s stock after buying an additional 12,200 shares during the period. ClariVest Asset Management LLC’s holdings in Halozyme Therapeutics were worth $787,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. Kennedy Capital Management Inc. raised its stake in Halozyme Therapeutics by 4.0% in the first quarter. Kennedy Capital Management Inc. now owns 73,681 shares of the biopharmaceutical company’s stock valued at $698,000 after buying an additional 2,818 shares during the last quarter. IFP Advisors Inc raised its stake in Halozyme Therapeutics by 300.8% in the first quarter. IFP Advisors Inc now owns 11,366 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 8,530 shares during the last quarter. BlackRock Group LTD raised its stake in Halozyme Therapeutics by 11.2% in the first quarter. BlackRock Group LTD now owns 128,945 shares of the biopharmaceutical company’s stock valued at $1,221,000 after buying an additional 12,956 shares during the last quarter. A.R.T. Advisors LLC raised its stake in Halozyme Therapeutics by 12.4% in the first quarter. A.R.T. Advisors LLC now owns 120,238 shares of the biopharmaceutical company’s stock valued at $1,138,000 after buying an additional 13,300 shares during the last quarter. Finally, Fisher Asset Management LLC raised its stake in Halozyme Therapeutics by 2.4% in the second quarter. Fisher Asset Management LLC now owns 725,011 shares of the biopharmaceutical company’s stock valued at $6,583,000 after buying an additional 17,231 shares during the last quarter. 80.41% of the stock is owned by institutional investors and hedge funds.
Shares of Halozyme Therapeutics Inc. (NASDAQ:HALO) traded down 4.28% during trading on Friday, reaching $10.06. 2,223,287 shares of the company traded hands. The stock’s 50 day moving average is $11.28 and its 200 day moving average is $10.13. The company’s market capitalization is $1.29 billion. Halozyme Therapeutics Inc. has a 1-year low of $6.96 and a 1-year high of $18.65.
Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.06. The company earned $33.30 million during the quarter, compared to the consensus estimate of $29.94 million. Halozyme Therapeutics had a negative return on equity of 234.15% and a negative net margin of 44.90%. Halozyme Therapeutics’s revenue was down 23.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.02 EPS. On average, analysts forecast that Halozyme Therapeutics Inc. will post ($0.91) EPS for the current year.
Several research firms have recently issued reports on HALO. Piper Jaffray Cos. restated an “overweight” rating and set a $15.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, June 23rd. Wells Fargo & Co. restated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, September 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $16.11.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics Inc. (NASDAQ:HALO).
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.